Targeted drug delivery and conventional medical management have shown to have a reduction in healthcare use and costs for cancer patients in comparison to conventional medical management alone, according to a new study from Medtronic.
The study found that there were significant cost savings to payers and fewer inpatient visits with shorter inpatient stays. It also showed that there were fewer emergency department visits for people who used targeted drug delivery (TDD) and conventional medical management (CMM).
Medtronic suggests that TDD therapy had a significant average overall cost savings of $63,498 with fewer opioid prescriptions per patient. The company says that TDD, when delivered through Medtronic’s SynchroMed II Infusion System, could be an alternative to oral opioids.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!